Ataraxis AI Secures $20.4M Series A Funding to Advance AI-Driven Cancer Diagnostics

The investment follows a recent clinical validation of Ataraxis AI’s first product, Ataraxis Breast, the world’s first AI-native prognostic and predictive platform for breast cancer.

Ataraxis AI, a leading AI-powered precision medicine company, has raised $20.4 million in Series A funding to accelerate its mission of transforming cancer diagnostics and treatment. 

AIX Ventures led the financing round, which received additional support from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors Giant Ventures and Obvious Ventures. 

Several prominent angel investors and healthcare pioneers participated, including Mario Schlosser (co-founder and former CEO of Oscar Health) and Ryan Fukushima (COO of Tempus). 

Additionally, leading researchers from OpenAI and DeepMind contributed to the round.

The investment follows a recent clinical validation of Ataraxis AI’s first product, Ataraxis Breast, the world’s first AI-native prognostic and predictive platform for breast cancer. 

A landmark study demonstrated that Ataraxis Breast is 30% more accurate than the current standard of care, marking a major advancement in breast cancer diagnostics. 

The funding will support the platform’s rollout for clinical use across the United States later this year and the development of new AI-powered treatment selection tools for additional cancer types.

Revolutionizing Cancer Diagnostics with AI

Ataraxis AI was founded by Jan Witowski, MD, PhD, and Krzysztof Geras, PhD, with the goal of reshaping oncology through advanced AI models. 

The company’s flagship foundation model, Kestrel, outperforms existing approaches by detecting complex, previously undetectable patterns associated with patient outcomes. 

Unlike other AI models that require vast amounts of data and computational power, Kestrel leverages novel optimization techniques to deliver superior accuracy with fewer resources.

“Ataraxis AI is redefining how cancer is diagnosed and treated,” said Jan Witowski, co-founder and CEO of Ataraxis AI. 

“This funding validates the transformative potential of our technology and enables us to scale our solutions to impact at least 50% of new cancer cases by 2030.”

Beyond breast cancer, Ataraxis AI is expanding Kestrel’s capabilities to support treatment selection across multiple cancer types. 

The company’s long-term vision is to develop AI copilots that assist oncologists in delivering highly personalized treatment strategies based on real-time insights.

The investment community sees Ataraxis AI as a pioneer in the convergence of AI and precision oncology.

“In the next five years, the world’s leading oncology centers won’t just have top physicians—they’ll have AI copilots revolutionizing diagnosis and treatment,” said Krish Ramadurai, Partner at AIX Ventures. 

“Ataraxis AI is at the forefront of this transformation, and Kestrel is setting a new benchmark for AI-driven cancer care. We are excited to support Jan and his team on this journey.”

Stay tuned for more such updates on Digital Health News.